Lower-price biosimilar competition for top-selling drug launching this weekend.
AbbVie’s ABBV rheumatoid arthritis drug Humira, one of the top-selling biopharmaceutical products of all time, will have new lower-cost competition starting Saturday. But even as nearly identical competitors become available at big discounts to Humira’s list price, they may be hard-pressed to knock the blockbuster drug off its perch, analysts say.
A biosimilar is a medicine that’s highly similar to another biologic — a pharmaceutical product made from living cells or organisms. Biologics’ complex structure and manufacturing process can make them expensive, so lower-cost biosimilars are key to increasing access to these drugs. Humira in recent years became a target amid the broader legislative and policy debate about high drug prices. The U.S. House Committee on Oversight and Reform published an investigation in 2021 that focused largely on Humira’s cost, saying the drug’s price had jumped 27 times since its 2003 launch, including by nearly 30% in one 10-month period. At the start of this year, AbbVie raised Humira’s list price another 8%, according to drug pricing data provider AnalySource.
Österreich Neuesten Nachrichten, Österreich Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Cheaper competition for Humira is hitting the market, but savings will depend on your insurancePatients who take the autoimmune disease treatment Humira may see some price relief when several lower-cost, biosimilar versions of the AbbVie drug reach the U.S. market in July.
Weiterlesen »
Cheaper competition for Humira is hitting the market, but savings will depend on your insurancePatients who take the autoimmune disease treatment Humira may see some price relief when several lower-cost, biosimilar versions of the AbbVie drug reach the U.S. market in July.
Weiterlesen »
Opioids no better than placebo for short-term lower back and neck painPeople who took the opioid oxycodone or a placebo for six weeks reported similar pain scores for acute discomfort in their lower back or neck
Weiterlesen »
Slovakian parliament votes in approval of lower crypto taxesIn addition, parliament members approved that crypto payments up to 2400 euros will not be taxed and excludes crypto income from a 14% health insurance contribution.
Weiterlesen »
U.S. stocks open modestly lower after paring premarket losses on GDP reportU.S. stocks opened modestly lower on Thursday after an upward revision to first-quarter annualized GDP growth pushed the main indexes to reverse some of their premarket losses. The Dow Jones Industrial Average fell 15 points, or 0.1%, to 33,834:
Weiterlesen »